Clinical Trial Update: Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients [Phase 3]

View source ↗

Summary

Phase 3 re-exposure study of intravenous pegloticase in symptomatic gout patients has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• KRYSTEXXA (pegloticase)

Snippet

Sponsor: Savient Pharmaceuticals | Conditions: Chronic Gout Refractory to Conventional Therapy | Phase 3 | Status: COMPLETED | Results posted: 2011-06-28